M3, Inc. (MTHRY)
OTCMKTS · Delayed Price · Currency is USD
6.50
-0.22 (-3.27%)
At close: Dec 12, 2025
M3, Inc. Revenue
M3, Inc. had revenue of 84.69B JPY in the quarter ending September 30, 2025, with 39.72% growth. This brings the company's revenue in the last twelve months to 330.97B, up 33.50% year-over-year. In the fiscal year ending March 31, 2025, M3, Inc. had annual revenue of 284.90B with 19.26% growth.
Revenue (ttm)
330.97B JPY
Revenue Growth
+33.50%
P/S Ratio
4.03
Revenue / Employee
21.55M JPY
Employees
15,360
Market Cap
9.01B USD
Revenue Chart
* This company reports financials in JPY.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 284.90B | 46.02B | 19.26% |
| Mar 31, 2024 | 238.88B | 8.07B | 3.49% |
| Mar 31, 2023 | 230.82B | 22.66B | 10.89% |
| Mar 31, 2022 | 208.16B | 38.96B | 23.03% |
| Mar 31, 2021 | 169.20B | 38.23B | 29.19% |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| American Oncology Network | 1.76B |
| Veradigm | 588.02M |
| Glass House Brands | 196.17M |
| Elite Pharmaceuticals | 122.89M |
| Silence Therapeutics | 25.83M |
| OpGen | 9.00M |
| Nuo Therapeutics | 2.61M |
| Northwest Biotherapeutics | 937.00K |
M3, Inc. News
- 4 years ago - M3, Inc.: Stand-Out Success Story Of Japanese Internet - Seeking Alpha
- 5 years ago - 5 Health Care Stocks Growing Fast - GuruFocus
- 5 years ago - 5 Telehealth Stocks for Long-Term Financial Fitness - Kiplinger